Who Supplies Carboplatin to India from ITALY

To import finished pharmaceutical formulations containing Carboplatin into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting Form 40 or 41, along with the necessary documentation, to the Drugs Controller General of India (DCGI). The timeline for obtaining these approvals can vary, but it typically ranges from several months to over a year, depending on the completeness of the application and the regulatory review process. Specific requirements for Carboplatin formulations under HS Code 30049047 include detailed product information, manufacturing site details, and compliance with Indian pharmacopoeia standards.

Imported Carboplatin formulations must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is mandatory, and a Certificate of Analysis (CoA) is required for each batch. Stability data demonstrating compliance with International Council for Harmonisation (ICH) Zone IV guidelines is necessary. Products must meet the standards set by the Indian Pharmacopoeia. Upon arrival, customs drug inspectors conduct port inspections to verify compliance with these requirements.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for importing pharmaceutical products, including mandatory import registration and licensing. The Production Linked Incentive (PLI) scheme has been introduced to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and Italy have facilitated smoother trade relations, but compliance with updated regulatory standards remains essential.

India imports finished Carboplatin formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic manufacturing capacity may not fully satisfy the market needs, leading to reliance on imports. The market size for Carboplatin formulations in India is substantial, with a growing number of patients requiring chemotherapy treatments.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049047 is 10%. The Integrated Goods and Services Tax (IGST) is levied at 12%, and the Social Welfare Surcharge (SWS) is 10% of the BCD. Additional levies may include Countervailing Duty (CVD) and Special CVD, depending on the product and country of origin. Exemptions and preferential rates may apply under specific trade agreements. The total landed duty percentage varies based on these factors.

Italy is a significant source for Carboplatin formulations due to its advanced pharmaceutical manufacturing capabilities, adherence to Good Manufacturing Practices (GMP), and the availability of patented formulations and specialized dosage forms. Other suppliers include China, Germany, and the United States, but Italy's reputation for quality and innovation provides a competitive advantage. Italy's share in India's Carboplatin import market is notable, reflecting strong trade relations and consistent product quality.

India imports Carboplatin formulations from Italy due to the availability of patented products, specialized dosage forms, and high-quality manufacturing standards. Certain formulations, such as specific injection types or combination therapies, may not be produced domestically, necessitating imports.

Compared to other sources like China, Germany, and the United States, Italy offers competitive pricing, superior quality, and compliance with international regulatory standards. Italy's unique advantage lies in its innovation and the availability of specialized Carboplatin formulations that meet specific therapeutic needs.

Potential risks include reliance on a single supplier, currency fluctuations, regulatory changes, quality control issues, and shipping disruptions. Past shortages have been minimal, but it's essential for importers to monitor these factors to mitigate potential impacts.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align procurement volumes with market demand to optimize costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure compliance with regulatory standards and quality benchmarks.

1. 1Obtain a valid Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT).
2. 2Register the manufacturing unit with CDSCO.
3. 3Submit Form 40 or 41 to CDSCO for drug registration.
4. 4Secure an Import License from CDSCO.
5. 5Obtain a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare, if required.
6. 6Engage a customs broker for clearance procedures.
7. 7Seek an advance ruling for HS Code 30049047, if necessary.

1. 1Certificate of Analysis (CoA) for each batch.
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Good Manufacturing Practices (GMP) certificate.
4. 4Drug Master File (DMF) for Carboplatin formulations.